12 results about "Antibiotic therapy" patented technology

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

This application provides a method and system for predicting urinary tract infections related to urodynamic examinations. It addresses the limitations of current preventative measures, where methods with high evidence levels and good efficacy, including antibiotic intravesical instillation and weekly oral cyclic antibiotic therapy, inevitably require antibiotic use. The method includes: acquiring urodynamic examination data from a target patient; analyzing the curve information in the urodynamic examination data to obtain a curve numerical sequence corresponding to a time axis; extracting a urodynamic feature set based on the curve numerical sequence; constructing a medical history feature set based on the target patient's medical history data; inputting the urodynamic feature set and the medical history feature set into a urinary tract infection risk prediction model to output a risk prediction result for urinary tract infection after urodynamic examination. The risk prediction result includes at least a risk score or risk stratification result.

The invention belongs to the technical field of prevention and control of drug-resistant bacteria, and particularly discloses a composite bactericidal composition and application thereof in preparation of a reagent for killing aeromonas hydrophila oxytetracycline drug-resistant strains. The minimum inhibitory concentration of the epsilon-polylysine to an aeromonas hydrophila oxytetracycline drug-resistant strain is as low as 3.125 g / mL. Meanwhile, the sterilization mechanism of the epsilon-polylysine on aeromonas hydrophila oxytetracycline drug-resistant strains is discussed through metabonomics research. On the basis, the application finds that various exogenous small molecule metabolites such as 2-phenylacetamide and the like are combined with epsilon-polylysine for use, so that the absorption of drug-resistant bacteria on epsilon-polylysine can be promoted, the sterilization effect of the epsilon-polylysine is effectively enhanced, and the problem of drug resistance of bacteria is solved. Therefore, when the epsilon-polylysine and the exogenous small molecule metabolite are jointly applied, compared with the existing single antibiotic therapy, the epsilon-polylysine has higher activity and better safety and operability in preparation of the reagent for resisting the aeromonas hydrophila oxytetracycline drug-resistant strain.

The invention discloses a gelled cell as well as a preparation method and application thereof. Relates to the field of synthetic biology and biomedicine. The gelated cell is a cell structure without cell viability, and comprises: a carrier cell framework comprising a cell membrane which retains the membrane protein content, the type and the lipid order of an original carrier cell; the intracellular hydrogel is formed in situ in the carrier cell framework through supramolecular host-guest interaction or cross-linking reaction, and is fused with the inner surface of a cell membrane; the antibacterial substance is loaded in the intracellular hydrogel; wherein pores are distributed on the cell membrane, the intracellular hydrogel is communicated with the external environment through the pores, and the loaded antibacterial substances are exposed. The gelated cell provided by the invention can simultaneously realize targeted delivery, contact sterilization and endotoxin adsorption, and avoids the problem of secondary inflammation caused by release of endotoxin in traditional antibiotic therapy and the problem of membrane protein loss or disordered arrangement in a cell membrane coating technology.

The invention relates to a novel topical pharmaceutical composition comprising ceftizoxime, a third-generation cephalosporin antibiotic, complexed with sulfobutyl ether-β-cyclodextrin (SBE-β-CD) to enhance solubility and stability in aqueous environments. The sterile, sprayable formulation is intended for direct topical use or dilution for the treatment and prevention of bacterial skin and wound infections. To overcome ceftizoxime's aqueous instability, the invention employs inclusion complexation with 2–10% w / v SBE-β-CD, prepared by shaking at 30°C for 72 hours followed by sterile filtration. Differential Scanning Calorimetry (DSC) confirms molecular encapsulation through suppression of the ceftizoxime melting peak, indicating loss of crystallinity. Antibacterial efficacy is demonstrated against Staphylococcus aureus and Escherichia coli using zone of inhibition assays. UV–Vis spectrophotometry at 258 nm confirms high linearity (R² = 0.998) for quantitative analysis. The formulation offers a stable, scalable, and patient-friendly alternative for localized antibiotic therapy and surgical prophylaxis with reduced systemic exposure.

The application discloses sulfhydrylated oxidized guar gum / sodium alginate microspheres and a preparation method and application thereof, and belongs to the field of biomedical materials. The sulfhydrylated oxidized guar gum and a sodium alginate base material are used to prepare and construct microspheres with pH response, colon targeting and intestinal adhesion by an emulsion gel method, the microsphere technology is used to embed probiotics, and the survival rate of the probiotics in gastric juice is improved. Through in-vitro verification, the method of embedding the microspheres successfully prevents the direct contact of the probiotics with a harsh environment, improves the ability of the probiotics to resist strong acid in the gastrointestinal tract, and enhances the adhesion and colonization effect of the probiotics in the intestinal tract. Through an animal experiment of simulating colitis, the LGG microspheres have the best treatment effect on colitis. Compared with a large number of side effects caused by antibiotic therapy, the treatment method has a certain clinical application prospect as a means with biological safety to treat inflammatory bowel disease.

The embodiment of the specification provides a nitrogen nanobubble water composition, a method for inhibiting helicobacter pylori and application, for inhibiting helicobacter pylori, the composition takes nitrogen nanobubble water as an active component, the bubble density of the nitrogen nanobubble water is, the average diameter is 60-100 nm, and the oxidation-reduction potential is 200-250 mV.The composition does not add any chemical antibiotic or antibacterial agent, achieves bacteriostasis through the physical energy and microenvironment regulation of nanobubbles, cannot induce the drug resistance of bacteria, can be used repeatedly for a long time, and fundamentally solves the drug resistance problem faced by traditional antibiotic therapy.The composition can be prepared into mouthwash, oral spray, oral cleaning solution, drinking water, functional beverage, oral cleaning appliance liquid, gastric perfusion liquid and various product forms, covers multiple application scenarios such as daily oral care, gastric health management and clinical medical treatment, and meets different use requirements.

The invention relates to a novel fusion protein, an immunogenic composition, a recombinant vaccine and the like for preventing and treating chlamydia psittaci infection. The fusion protein provided by the invention contains fusion proteins coded by four genes of rplE, rpsC, rpsE and rpsG, and has good immunogenicity. Compared with a traditional antibiotic therapy, the nucleic acid vaccine constructed by the fusion protein can provide an effective immune protection effect, remarkably inhibit chlamydia psittaci infection, effectively eliminate chlamydia psittaci colonization and avoid repeated infection, and has a wide application prospect.

The invention discloses a preparation method and application of clostridium butyricum-sourced extracellular vesicles, the extracellular vesicles (CBEVs) are separated and purified from clostridium butyricum, and through structural characterization, metabonomics and multi-function verification, the extracellular vesicles (CBEVs) have a good application prospect. Results show that the extracellular vesicle has multiple effects of resisting helicobacter pylori activity and gastric mucosa penetrability, inhibiting bacterial adhesion and biofilm formation, reducing gastric mucosa inflammatory factors and the like, and is non-toxic to gastric epithelial cells. Compared with the existing antibiotic and probiotic therapy, the vesicle has a remarkable antibacterial effect on sensitive helicobacter pylori and drug-resistant strains, solves the problems of high drug resistance, large side effect and the like of the existing antibiotic therapy for helicobacter pylori, avoids the problem of viable bacterium colonization failure of probiotics, and is higher in safety and suitable for long-term treatment and prevention. In addition, due to the natural source characteristic, excellent biocompatibility is achieved, and an innovative direction is provided for developing novel antibacterial drugs.

The present application relates to the technical field of biological medicine, in particular to an antibody against staphylococcus aureus enterotoxin B and application thereof. The heavy chain variable region of the antibody provided in the present application comprises CDR sequences as shown in SEQ ID NO. 1-3, and the light chain variable region comprises CDR sequences as shown in SEQ ID NO. 9-11. The antibody has high affinity and can specifically bind to staphylococcus aureus SEB, can block the combination of SEB and MHC II / TCR, significantly inhibit cytokine storm, and exhibit dose-dependent protection effect in the MRSA systemic infection model, and can be used for treating, preventing or diagnosing staphylococcus aureus infection, and provides a non-antibiotic therapy solution for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health value.

The present disclosure relates to a method for predicting the appropriateness of antibiotic use in a patient with an infectious disease and a device thereof, comprising receiving a bio-signal data, blood test data, and clinical characteristic data for a subject; and predicting appropriateness of antibiotic therapy for the subject based on the received bio-signal data, blood test data, and clinical characteristic data using a prediction model configured to predict the appropriateness of antibiotic use with the bio-signal data, blood test data, and clinical characteristic data as input.

The invention belongs to the technical field of biology, and relates to application of bacteriophage AS25-GD in preparation of drugs for treating or preventing and controlling aquaculture bacterial diseases. The bacteriophage can effectively inhibit the growth of aeromonas salmonicida and crack aeromonas hydrophila, and in addition, the bacteriophage or a method of combining the bacteriophage with antibiotics is used for replacing a pure antibiotic therapy, so that the drug resistance of bacteria to antibiotics can be effectively reduced.